^(131)I联合ALSS治疗甲亢合并重型肝炎疗效分析  

作　　者：张成席[1] 胡继清[1] 何雨洁[1] 

机构地区：[1]湖南省常德市第一人民医院核医学科,415000

出　　处：《当代医学》2013年第4期13-14,共2页Contemporary Medicine

摘　　要：目的探讨^(131)I结合人工肝支持辅助系统(ALSS)治疗甲状腺功能亢进(甲亢)合并重型肝炎的安全性及有效性。方法回顾性分析55例接受^(131)I联合ALSS治疗的甲亢合并重型肝炎患者的临床资料(观察组),并与同期仅接受^(131)I治疗的30例甲亢合并重型肝炎患者的临床资料进行比较(对照组)。比较两组患者治疗前、治疗后的甲状腺激素水平以及肝功能的各项指标变化,以及临床效果。结果治疗前两组患者在甲状腺激素和肝功各项指标间差异不显著(P>0.05),治疗后两组患者各项指标均有所改善(P<0.05),其中观察组改善程度显著高于对照组(P<0.01),观察组共治愈43例,好转10例,2例无效(死亡),总有效率达96.3%,显著高于对照组70.0%(P<0.05)。结论甲亢合并重型肝炎治疗的关键是快速控制甲亢;ALSS可大大提高^(131)I治愈率和安全性。Objective To discuss the safety and efficacy of iodine 131 combined with artificial liver support system（ALSAS） to treat the hyperthyroidism merger severe hepatitis. Methods Clinical data of 55 patients with hyperthyroidism merger severe hepatitis treated by iodine 131 combined with artificial liver support system were retrospective, and compared with 30 patients treated only by iodine 131, the thyroid hormone level and change of liver function＇s each index before and after treatment of two groups were compared. Results There was no difference between two groups in all the index, however after treatment all the index of two groups were improved, and that＇s of observation group were better than control group（P〈0.05）, and there was 43 cases cured, 10 cases improved and 2 cases died, the total efficiency of observation group was 96.3%, significantly than control group（P〈0.05）. Conclusion The treatment of hyperthyroidism merger severe hepatitis is the key to control the hyperthyroidism quickly; ALSS application can greatly improve the 131 iodine cure rate and security.

关 键 词：甲状腺功能亢进 重型肝炎 人工肝支持系统 

分 类 号：R581.1[医药卫生—内分泌] R575.1[医药卫生—内科学]